A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B) ☆
Titel:
A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B) ☆
Auteur:
Sakai, H. Tsurutani, J. Ozaki, Y. Ishiguro, H. Nozawa, K. Yamanaka, T. Aogi, K. Matsumoto, K. Iwasa, T. Tokiwa, M. Tsuneizumi, M. Miyoshi, Y. Kitagawa, C. Yamamoto, M. Takano, Y. Imamura, C.K. Chiba, Y. Takiguchi, D. Ezumi, T. Takano, T.